- Projects
- Applications
Sirigen is developing products where its novel polymers are bound, either covalently or electrostatically, to an antibody or hybridisation probe plus dyes.
Two types will be available in the field of immunology
Universal Conjugates [Polymer-Antibody-Dye]
These biological conjugates incorporate frequently used Antibodies in life-science research. The Sirigen conducting polymer operates at a specific excitation wavelength providing one product. By utilising different polymers with different excitation wave lengths Sirigen will present to the market a range of conjugates for each antibody selected thereby accommodating the variety of different commercially available fluorimeters.
Custom Conjugates [Polymer-Antibody-Dye]
These custom conjugates by definition are custom made to incorporate specific antibodies provided by a collaborating partner which incorporate polymers operating at excitation wavelengths governed by the specification of the collaborating company’s instrumentation.
The same approach ids being taken in the molecular area, producing universal and customised conjugates of Hybridisation Probe-Polymer-Dye.
The current science of clinical diagnostics
Increasing cost pressures in healthcare is driving the need for quick and accurate diagnoses, plus the monitoring of the efficacy of long term drug treatments.
In clinical diagnostics, healthcare providers, hospitals, and clinical labs require speedy, cost effective, and highly accurate tests to indicate the presence of certain disease causing pathogens. There are currently two basic approaches for diagnosing many of these diseases:
Immunodiagnostics - indirect tests for the presence of markers involved in the immune response (antibodies) that often do not appear until the disease has progressed significantly.
Molecular diagnostics - nucleic-acid testing (NAT) uses a combination of reagents and instrumentation to perform purification, amplification and detection to signify the presence of specific DNA or RNA to indicate illness or predisposition to illness.
The Pharmaceutical companies are constantly searching for new and novel biomarkers to help identify new therapeutic agents to manage specific disease states.